leukemia, myelomonocytic, chronic
Showing 1 - 23 of 23
Immune System Diseases, Autoimmune Diseases, Inflammation Trial (observational cohort study)
Not yet recruiting
- Immune System Diseases
- +15 more
- observational cohort study
- (no location specified)
Jul 23, 2023
MDS, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic Trial in Newcastle (Subcutaneous azacitidine, Oral
Not yet recruiting
- Myelodysplastic Syndromes
- +3 more
- Subcutaneous azacitidine
- Oral decitabine/cedazuridine
-
Newcastle, New South Wales, AustraliaCalvary Mater Newcastle
May 29, 2023
Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute Trial in Worldwide (Azacitidine,
Active, not recruiting
- Myelodysplastic Syndrome
- +2 more
-
Daphne, Alabama
- +241 more
Dec 23, 2022
MDS, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute Trial in Worldwide (Azacitidine, Pevonedistat)
Completed
- Myelodysplastic Syndromes
- +2 more
-
Birmingham, Alabama
- +58 more
Aug 24, 2022
Azacitidine in International Prognostic Scoring System
Recruiting
- Myelodysplastic Syndromes
- +2 more
-
Hefei, Anhui, China
- +16 more
Sep 6, 2022
MDS, Leukemia, Myelomonocytic, Chronic Trial (decitabine, Spartalizumab, Sabatolimab)
Not yet recruiting
- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
- decitabine
- +5 more
- (no location specified)
Aug 5, 2022
Primary Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia Trial in Toronto (Observational)
Recruiting
- Primary Myelofibrosis
- +9 more
- Observational
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Apr 11, 2022
Leukemia, Myeloid, Acute, MDS, Leukemia, Myelomonocytic, Chronic Trial in Worldwide (H3B-8800 (RVT-2001))
Recruiting
- Leukemia, Myeloid, Acute
- +2 more
- H3B-8800 (RVT-2001)
-
Stanford, California
- +26 more
Mar 23, 2022
MDS, Leukemia, Myelomonocytic, Chronic Trial in Worldwide (Guadecitabine, Treatment Choice)
Completed
- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
- Guadecitabine
- Treatment Choice
-
Duarte, California
- +95 more
Sep 1, 2021
Leukemia, Myeloid, Acute, MDS, Leukemia, Myelomonocytic, Chronic Trial in Duesseldorf (Lenalidomide, Azacitidine, Donor
Completed
- Leukemia, Myeloid, Acute
- +2 more
- Lenalidomide
- +2 more
-
Duesseldorf, NRW, GermanyUniversity Hospital Duesseldorf, Dept. of Hematology, Oncology a
May 26, 2020
Recently Diagnosed Myelodysplastic Syndrome/Chronic
Completed
- Myelodysplastic Syndrome
- Leukemia, Myelomonocytic, Chronic
- Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion
-
Vitoria, Alava, Spain
- +49 more
Jan 23, 2020
MDS, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute Trial in United States (oral azacitidine)
Completed
- Myelodysplastic Syndromes
- +2 more
- oral azacitidine
-
La Jolla, California
- +7 more
Nov 7, 2019
Patients Receiving Azacitidine in Daily Clinical Practice in
Completed
- Myelodysplastic Syndromes
- +2 more
- (no location specified)
Jul 23, 2019
Acute Myeloid Leukemia, MDS, Agnogenic Myeloid Metaplasia Trial in Houston (Dasatinib (BMS-354825))
Completed
- Acute Myeloid Leukemia
- +7 more
- Dasatinib (BMS-354825)
-
Houston, TexasThe University of Texas M.D. Anderson Cancer Center
May 2, 2019
MDS, Leukemia, Myelomonocytic, Chronic Trial in France, Germany (Azacitidine, Volasertib)
Terminated
- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
-
Marseille, France
- +13 more
Sep 11, 2018
MDS, Leukemia, Myelomonocytic, Chronic Trial in Japan (Azacitidine, Volasertib)
Completed
- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
-
Aichi, Nagoya, Japan
- +3 more
Oct 23, 2017
Leukemia, Myelomonocytic, Chronic Trial in Gothenburg, Stockholm (Cohort 1, Ceplene® and Proleukin®, Cohort 2, Ceplene® and
Unknown status
- Leukemia, Myelomonocytic, Chronic
- Cohort 1, Ceplene® and Proleukin®
- +2 more
-
Gothenburg, Sweden
- +1 more
Dec 18, 2017
MDS, Leukemia, Myelomonocytic, Chronic, Angiogenesis Trial in Toronto (Lenalidomide and melphalan)
Completed
- Myelodysplastic Syndromes
- +2 more
- Lenalidomide and melphalan
-
Toronto, Ontario, CanadaSunnybrook Health Sciences Centre, Odette Cancer Center
Jun 8, 2017
GVHD, MDS, Leukemia Trial run by the NHLBI (RFT5-SMPT-dgA, Isolex system)
Completed
- Graft vs Host Disease
- +9 more
- RFT5-SMPT-dgA
- Isolex system
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 21, 2016
Korean Post-marketing Surveillance for Sprycel®
Completed
- Leukemia, Myelomonocytic, Chronic
- Leukemia-Lymphoma
-
Seoul, Korea, Republic ofLocal Institution
Apr 25, 2016
MDS, Leukemia, Myelomonocytic, Chronic Trial in Durham (Sorafenib)
Terminated
- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
-
Durham, North CarolinaDuke University Medical Center
Mar 21, 2016